Par launches generic Afinitor

Par Pharmaceutical is debuting everolimus tablets in dosage strengths of 2.5 mg, 5 mg and 7 mg.

The product, which is the generic of Novartis’ Afinitor, is available for immediate shipping.

"We are pleased to bring the first generic Afinitor to market and provide patients with a lower-cost option," said Domenic Ciarico, Endo executive vice president and chief commercial officer, sterile & generic. "This launch is a testament to Par's expertise in manufacturing technically challenging products while maintaining excellence in quality."

Afinitor 2.5 mg, 5 mg and 7 mg tablets had a market value of approximately $412 million over the last four quarters, according to IQVIA.